PLSE Share Price Performance
US$14.20
-3.07 (-17.78%)
35.5% undervalued intrinsic discount
US$22.00
Fair Value
Price US$14.20
AnalystConsensusTarget US$22.00
Fair ValueUS$22.00
Share Pricen/a
Pulse Biosciences, Inc. Stock Price
- 1 Narratives written by author
- 0 Comments on narratives written by author
- 3 Fair Values set on narratives written by author
PLSE Community Narratives
AN
Fair Value US$22 35.5% undervalued intrinsic discount
Nanosecond Pulse Field Ablation Advancements Will Transform Thyroid And Cardiac Care Over Time
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
Nanosecond Pulse Field Ablation Advancements Will Transform Thyroid And Cardiac Care Over Time
Catalysts About Pulse Biosciences Pulse Biosciences develops and commercializes proprietary nanosecond pulse field ablation platforms for minimally invasive treatment of soft tissue and cardiac disorders. What are the underlying business or industry changes driving this perspective?Read more
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
AN
US$22
35.5% undervalued intrinsic discount
AnalystConsensusTarget Fair Value
Revenue
601.51% p.a.
Profit Margin
0.13%
Future PE
492.57x
Price in 2028
US$0.27
Trending Discussion
Recently Updated Narratives
AN
Nanosecond Pulse Field Ablation Advancements Will Transform Thyroid And Cardiac Care Over Time
Fair Value: US$22 35.5% undervalued intrinsic discount
1 followerusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Pulse Biosciences, Inc. Key Details
Last Reported Earnings
Sep 30, 2025
Next Reporting Earnings
n/a
- -1.10
- -224.42%
- -86,898.84%
- 0%
About PLSE
- Founded
- 2014
- Employees
- 75
- CEO
- WebsiteView website
Pulse Biosciences, Inc. operates as a novel bioelectric medicine company. It offers CellFX System, a novel Nanosecond Pulsed-Field Ablation delivery platform to treat benign lesions of the skin; CellFX nsPFA Percutaneous Electrode system for soft tissue ablation in surgical setting; CellFX nsPFA Cardiac Clamp designed for use in surgical treatment of atrial fibrillation (AF); CellFX nsPFA 360° Cardiac Catheter designed to provide a circumferential, or circular, ablation in a single treatment cycle; and The CellFX Consol, a tunable, software-enabled, and console-based platform designed to accommodate the clinical workflow preferred by physicians. The company was formerly known as Electroblate, Inc. and changed its name to Pulse Biosciences, Inc. in December 2015. Pulse Biosciences, Inc. was incorporated in 2014 and is headquartered in Miami, Florida.
